TrianglePUBLICATIONS · 33539744
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2021 Feb
- First author
- Pignata S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Pignata S
- type
- Author
- name
- Lorusso D
- type
- Author
- name
- Joly F
- type
- Author
- name
- Gallo C
- type
- Author
- name
- Colombo N
- type
- Author
- name
- Sessa C
- type
- Author
- name
- Bamias A
- type
- Author
- name
- Salutari V
- type
- Author
- name
- Selle F
- type
- Author
- name
- Frezzini S
- type
- Author
- name
- De Giorgi U
- type
- Author
- name
- Pautier P
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Pignata S
- type
- Author
- name
- Lorusso D
- type
- Author
- name
- Joly F
- type
- Author
- name
- Gallo C
- type
- Author
- name
- Colombo N
- type
- Author
- name
- Sessa C
- type
- Author
- name
- Bamias A
- type
- Author
- name
- Salutari V
- type
- Author
- name
- Selle F
- type
- Author
- name
- Frezzini S
- type
- Author
- name
- De Giorgi U
- type
- Author
- name
- Pautier P
- type
- Author
- bibliography ids
- nci-bib-2c305eb5a57d0216c9e6390a
- book metadata
- content sha256
- 15a1315fe190337da5250044a3b278cc26231a199285548a9cd10266f3a25c25
- document type
- citation
- dois
- 10.1016/S1470-2045(20)30637-9
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:33539744
- immutable id
- pubmed:33539744@15a1315fe190337da5250044a3b278cc26231a199285548a9cd10266f3a25c25
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 2
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 267-276
- volume
- 22
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 33539744
- provenance
- batch id
- 79f1021053e858d13ff3
- provider
- NCBI PubMed ESummary
- record sha256
- d2a7c456991646a47a33d13e52f3d22e1a9f53fd6a460b92055ad16d636ac1db
- response sha256
- 671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
- retrieved at
- 2026-09-09T23:47:59.098265+00:00
- publication date
- display
- 2021 Feb
- precision
- month
- year
- 2021
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Preserved source evidence · Not medical advice